Most Recent Articles by Da Hee Han, PharmD
The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.
This is the first device authorized for marketing that provides a screening decision without the need for clinician interpretation.
The new Essure labeling restricts the sale and distribution of the device to only health care providers and facilities that provide information to patients about the risks and benefits of this device.
The Food and Drug Administration (FDA) has issued a discontinuation notice for Bydureon (exenatide extended-release; AstraZeneca) for injectable suspension Single Dose Trays.
The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.
More Articles by Da Hee Han, PharmD
Endocrinology Advisor Articles
- ADA Releases Updated Guidelines for Managing Pediatric Type 1 Diabetes
- Relationship Between HbA1c and Coronary Artery Disease
- Intermittent vs Continuous Energy-Restricted Diet: Effects on Glycemic Control and Weight Loss T2D
- The Obesity Paradox in Diabetes: Conceptual and Clinical Approaches
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Self-Administered Contraceptive Vaginal System Approved for Up to 1 Year of Use
- Predictors of Weight Loss in Postpartum Women With Gestational Diabetes
- Genetic Screening May Predict Osteoporosis, Fracture Risk
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- AMA Adopts Policy on Augmented Intelligence